US2005164257A1PendingUtilityA1

Proteins producing an altered immunogenic response and methods of making and using the same

Priority: Apr 15, 1998Filed: Dec 22, 2004Published: Jul 28, 2005
Est. expiryApr 15, 2018(expired)· nominal 20-yr term from priority
G01N 33/6854A61K 38/00C12N 9/20C12N 9/54C12N 9/6424C12Y 302/01004G01N 33/505C12N 9/2437
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein. Alternatively, T-cell epitopes are mutated to produce increased immunogenic reactions. Moreover, naturally occurring proteins are provided.

Claims

exact text as granted — not AI-modified
1 . A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest, wherein said T-cell epitope of said polypeptide of interest is altered to produce said variant, and wherein said polypeptide of interest is an enzyme selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrases, reductase, oxidase, isomerase, transferase, kinase and phosphatase.  
     
     
         2 . (canceled)  
     
     
         3 . (canceled)  
     
     
         4 . (canceled)  
     
     
         5 . The variant of  claim 1  wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.  
     
     
         6 . (canceled)  
     
     
         7 . The variant of  claim 1  wherein said T-cell epitope is altered with amino acid substitutions.  
     
     
         8 - 28 . (canceled)  
     
     
         29 . A variant of a polypeptide of interest comprising at least one T-cell epitope, wherein said variant differs from said polypeptide of interest by having at least one altered T-cell epitope, such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest, wherein said at least one T-cell epitope of said polypeptide of interest is altered to produce said variant , and wherein said polypeptide of interest is an enzyme selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrases, reductase, oxidase, isomerase, transferase, kinase and phosphatase.  
     
     
         30 . The variant of  claim 29 , wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.  
     
     
         31 . The variant of  claim 29 , wherein said T-cell epitope is altered with amino acid substitutions.

Join the waitlist — get patent alerts

Track US2005164257A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.